Serotonin 1A Agonists and Cognition in Schizophrenia

Schizophrenia Clinical Trial

Official title:

Serotonin 1A Agonists and Cognition in Schizophrenia

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00178971
• Other study ID #: 020724
• Status: Completed
• Phase: Phase 3
• First received: September 12, 2005
• Last updated: June 5, 2017
• Start date: January 2003
• Est. completion date: October 2004

Study information

• Verified date: June 2017
• Source: Northwestern University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Examines cognitive functioning in patients with schizophrenia or schizoaffective disorder who have been treated with antipsychotic medications. Patients will be assigned to take active medication (Buspar)or placebo along with their prescribed antipsychotic medication for six weeks. Patients' memory and problem-solving ability will be tested before and after medication.

Description:

Examines cognitive functioning in patients with schizophrenia or schizoaffective disorder who have been treated with olanzapine or risperidone for at least three months randomized to receive adjunctive treatment with a 5-HT1A agonist (buspirone, 15-30 mg/day)or placebo.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 60
• Est. completion date: October 2004
• Est. primary completion date: October 2004
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

Subjects must meet all of the following criteria to be eligible for participation in the current research study.

1. Subjects will be males and females between 18-65 years of age;

2. Subjects will have a definite diagnosis by DSM-IV criteria for Schizophrenia or Schizoaffective Disorder;

3. The subjects or their legal guardian must sign the informed consent;

4. Subjects currently being treated with olanzapine or risperidone for a duration of at least 3 months

Exclusion Criteria:

1. Subjects who are pregnant or lactating

2. Subjects who have brain damage and/or neurological disorders

3. Subjects who have current substance dependence

4. Subjects unable to provide informed consent

Related Conditions & MeSH terms

• Psychotic Disorders
• Schizoaffective Disorder
• Schizophrenia

Intervention

Drug:
• adjunctive treatment with buspirone
buspirone 15-30 mg qd
• placebo
placebo

Locations

Country	Name	City	State
United States	Psychiatric Hospital at Vanderbilt	Nashville	Tennessee

Sponsors (2)

Lead Sponsor	Collaborator
Northwestern University	National Alliance for Research on Schizophrenia and Depression

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	This study will examine the effect on cognition of the addition of buspirone compared with addition of a sugar pill to patients treated with olanzapine or risperidone		six weeks